Amy Huang （黃秀美女士）
General Manager of OBI Pharma Inc.
台灣浩鼎總經理
Ms. Amy Huang will be giving a special talk together with Dr. Tong-Young Lee (Founder and CEO of Celtec Inc.) on Aug. 5 (Sat.) 5:15 pm – 6:15 pm, Room B103, to share their personal experiences and stories.
Ms. Huang joins OBI, Inc. after a distinguished career at GlaxoSmithKline, where she was Vice President and Regional Director responsible for all commercial operations in China and Hong Kong. Ms. Huang is an inspirational leader and successful executive with numerous awards and achievements, including Outstanding Pharmaceutical Manager (Taiwan) and GSK´s Inspirational Leadership Award (2005). Since the merger of Glaxo Wellcome and SmithKline Beecham in 2001, she presided over record country performances during a turbulent period of regulation in Taiwan’s pharmaceutical industry. During her tenure as Managing Director of SmithKline Beecham Taiwan, she oversaw the launches of novel products, such as Engerix B, Tagamet, Augmentin, Avandia, and Seretide, representing some of the most successful.
About OBI Pharma, Inc. 台灣浩鼎
OBI Pharma, Inc., was founded in 2002. Its focus is on the “Unmet Medical Needs” in challenging diseases throughout the world, such as Cancer & Infectious Diseases. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics. OBI’s core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company has an exciting pipeline of products built on a ground-breaking carbohydrate synthesis discovery platform. OBI works in close collaboration with prestigious research institutes, including Academia Sinica of Taiwan and the Memorial Sloane-Kettering Cancer Center of the US.